Financial PerformanceThe company reported total revenues of $12.938bn, beating consensus of $12.571bn by 3%.
Guidance And GrowthAZN raised financial guidance for FY24, guiding to mid-teens percentage increase for total revenue and core EPS.
Product PerformanceKey products mostly outperformed consensus, driven by Symbicort (+28%), Farxiga (+5%) and Ultomiris (+4%).